Compare AbCellera Biologics Inc (ABCL) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs IQIYI Inc - ADR — how do they compare? AbCellera Biologics Inc trades at $8.96 (market cap $2.85B), while IQIYI Inc - ADR trades at $1.35 (market cap $1.31B). The key difference: AbCellera Biologics Inc is far larger — about 2.2× IQIYI Inc - ADR's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals.
| ABCL | IQ | |
|---|---|---|
Market Cap | $2.85B | $1.31B |
Sector | Health | Media |
52-Week High | $9.76 | $2.79 |
52-Week Low | $2.78 | $0.96 |
Enterprise Value | $2.45B | $2.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
iQIYI (IQ) trades at $1.33, up 3.1% in 24 hours, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q1 2026 revenue of $915.2M, missing expectations, but beat EPS estimates. Valuation ratios show low P/S and P/B, but negative profitability metrics persist. Recent news highlights AI platform growth and leadership changes, with analyst consensus leaning buy.
Outlook: Potential upside exists from AI initiatives and cost controls, but risks include revenue declines, regulatory pressures, and negative cash flow projections. Investors should weigh low valuation against profitability challenges and China market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
